rafapress / Shutterstock.com
8 July 2022Americas
Federal Circuit rejects ADHD generic drug challenge
A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.
Editor's picks
Editor's picks
Americas
10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.
Americas
10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.